Migraine Therapeutics Market – Global Industry Analysis and Forecast (2022-2029)

Migraine Therapeutics Market is expected to reach USD 6.47 billion by 2029, with a CAGR of 4.8 % between 2022 and 2029.

The research gives a comprehensive perspective of the market by combining qualitative and quantitative data. It examines the global Migraine Therapeutics Market and provides forecasts for the key segments. It also includes market size and forecast estimates for five key regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America, for the years 2021 to 2029. The Migraine Therapeutics Market is further split into countries and markets within each location.

To know about the Research Methodology :- Request Free Sample Report
Migraine Therapeutics Market Dynamics
Prevalence and diagnosis of migraines are on the upsurge.

A significant increase in migraine incidence is one of the primary reasons driving the market growth. Improved payment regulations for migraine therapies, as well as increased demand for precision medications, are also helping the market. Market growth is being fueled by rising demand for electrical nerve stimulating devices to treat migraines, as well as the anticipated approval of new classes of late-stage pipeline drugs.

Significant progress is being made in the treatment of persistent migraines as a prophylactic measure.

The significant advancements should cause us to reconsider our approaches to this devastating disease, empowering us to remain vigilant and continue scientific clinical research, while also keeping in mind that the only way to improve chronic migraine detection is to develop a common, shared clinical and scientific management strategy. This distinction between phenotypic and biological indicators sheds light on aspects of clinical governance that had previously been overlooked. It is our responsibility to guarantee that innovative and evolving therapeutic options, such as OBT-A and anti-CGRP monoclonal antibodies, are fully utilized in a larger preventive culture in order to substantially reduce the human, social, and economic consequences of this devastating disease.

Restraints: Alternative remedies such as homeopathy, as well as the limits of conventional migraine medicines, as well as a drop in clinical visits and procedural treatment of migraines owing to social distancing conventions, are expected to impede market growth from 2022 to 2029.

Opportunities

Increased R&D investment in migraine therapy has led to pipeline products, which will result in manufacturers bringing new products into the market, growing demand, and technical improvements or the treatment of acute migraine has increased. Several research projects are now underway, which will likely provide manufacturers a competitive edge in producing new, innovative, and enhanced migraine treatment drugs as well as additional migraine treatment market potential.

Triptans are expected to grow at a healthy CAGR during the forecast period.

Triptans are a newer family of medication that reduces inflammation and constricts blood vessels in the brain, thus eliminating a migraine. Triptans inhibit pain pathways by constricting blood arteries in the brain. These ergotamines are more migraine-specific than prior ergotamines, according to research. Some of the triptans available include almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, sumatriptan with naproxen, and zolmitriptan. A single-tablet combination of sumatriptan and naproxen sodium (Treximet) has been demonstrated to be more effective than either medicine alone in reducing migraine symptoms.
Migraine Therapeutics Market Regional Insight
The global migraine therapeutics market is dominated by North America. North America's strong position in the global migraine treatment market is due to the presence of a well-established pharmaceutical sector in the area. Furthermore, there is a significant demand for migraine medications in the region due to a greater knowledge of the hazards of migraine and how it affects the quality of life.

The increased focus of suppliers on emerging markets such as Asia-Pacific and Latin America and the Caribbean (LAMEA) is likely to promote market growth. Due to increased demand for improved healthcare facilities and advances in healthcare infrastructure, Asia-Pacific is expected to develop significantly in the future. Secondly, because the developed markets are somewhat saturated, this region provides the exceptional potential for venture capitalists and investors. In the forecast period, the bio-decontamination market in the Asia Pacific is expected to grow steadily. This is attributable to an increase in the number of hospitals and clinics, as well as government attempts to improve healthcare infrastructure. APAC is also the world's largest exporter of pharmaceutical products, highlighting the need of ensuring high-quality medications for export and providing chances for market participants to access these markets.
Report Objectives:
• Landscape analysis of the Migraine Therapeutics Market
• competitive benchmarking
• Past and current status of the industry with the forecasted market size and trends
• Evaluation of potential key players that include market leaders, followers, and new entrants
• Technology trends
• The potential impact of micro-economic factors on the market
• External and Internal factors affecting the market have been analyzed

The report also helps in understanding the Migraine Therapeutics Market dynamics, and structure by analyzing the market segments to project the Migraine Therapeutics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Migraine Therapeutics Market make the report investor’s guide.
Migraine Therapeutics Market Scope: Inquire before buying



Global Migraine Therapeutics Market


Report Coverage
Details


Base Year:
2021
Forecast Period:
2022-2029


Historical Data:
2017 to 2021
Market Size in 2021:
US $ 4.45 Bn.


Forecast Period 2022 to 2029 CAGR:
4.8%
Market Size in 2029:
US $ 6.47 Bn.


 Segments Covered:
by Therapeutics
• Pain-relieving Medications
o Analgesics
o Triptans
o Ergot Alkaloids
o Others
• Preventive Medications
o Blood pressure-lowering Medications
o Anticonvulsant Drugs
o Calcitonin Gene-related Peptide (CGRP) Antagonists
o Other Preventative Therapies



by Route of Administration
• Oral & Nasal
• Injectables



Migraine Therapeutics Market, by Region
• North America
• Europe
• Asia pacific
• The Middle East and Africa
• South America
Migraine Therapeutics Market: Key Players
• Endo International plc
• Pfizer Inc.
• Aegis Therapeutics, LLC.
• Aeriel BioPharma
• Alder BioPharmaceuticals Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• CoLucid Pharmaceuticals Inc.
• Dr. Reddy’s Laboratories Ltd.
• IntelGenx Corp.
• Johnson & Johnson
• Kowa Pharmaceuticals America
• Luitpold Pharmaceuticals
• Teva Pharmaceutical Industries LTD.
• Valeant Pharmaceuticals International, Inc,
• WINSTON PHARMACEUTICALS, Inc.
• Zogenix Inc.
• Abbott Laboratories
• AstraZeneca plc
• GlaxoSmithKline plc.

Frequently Asked Questions

1. What is the projected market size & growth rate of the Migraine Therapeutics Market?
Ans- The Migraine Therapeutics Market was valued at USD 4.45 billion in 2021 and is projected to reach USD 6.47 billion by 2029, growing at a CAGR of 4.8 % during the forecast period.

2. What is the key driving factors for the growth of the Migraine Therapeutics Market?
Ans- A significant increase in migraine incidence is one of the primary reasons driving the market growth.

3. Which Region accounted for the largest Migraine Therapeutics Market share?
Ans- The global migraine therapeutics market is dominated by North America.

4. What makes the North America a Lucrative Market for Migraine Therapeutics Market?
Ans- North America's strong position in the global migraine treatment market is due to the presence of a well-established pharmaceutical sector in the area.

5. What are the top players operating in the Migraine Therapeutics Market?
Ans- Endo International plc, Pfizer Inc., Aegis Therapeutics, LLC., Aeriel BioPharma, and Alder BioPharmaceuticals Inc.